Navigation Links
Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development
Date:4/28/2008

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development.

Dr. Lee joins Particle Sciences following more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Most recently, he served Novavax, Inc. as Vice President of Pharmaceutical Development. Prior to that, Dr. Lee held senior management positions at Lyotropic Therapeutics, Inc. and IMCOR Pharmaceutical Co. Dr. Lee is currently serving as a scientific advisor for NanoScan Imaging, LLC, and Savara Pharmaceutical.

From 1990 to 2002, Dr. Lee held various R&D positions within Sterling Winthrop Pharmaceuticals Research Division, NanoSystems, and elan Drug Delivery, Inc. His areas of expertise include Preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs. He maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

Dr. Mitchnick comments that "Robert brings a wealth of experience to the Particle Sciences team. His background fits perfectly with our continued focus on advanced delivery systems. Particle Sciences typically deals with difficult to solubilize API's and nanotechnology based systems. Rob has deep experience in these areas as well as in clinical trial manufacturing, another area in which Particle sciences is expanding."

Dr. Lee received a Ph.D. in Physical Bioorganic Chemistry under the direction of Professor Thomas C. Bruice from the University of Califo
'/>"/>

SOURCE Particle Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Hiemstra Appoints Robert C. Glines as Director of Business Development
5. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
6. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
7. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
8. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
9. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
(Date:7/28/2015)... NESS ZIONA, Israel ... CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company ... repair products, today announced that Shomrat Shurtz has ... September 20, 2015.      (Photo: ... brings over 25 years of experience in marketing, ...
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... LLC announced today that the first patient has ... support a new fixed-dose combination (FDC) therapy for ... known as 572-Trii, will combine the investigational integrase ... reverse transcriptase inhibitor (NRTI) Kivexa®/Epzicom® (ABC/3TC). ...
... could jumpstart the promising field of cell therapy, in which ... of diseases and tissue defects, researchers at Brigham and Women,s ... the key challenges associated with the procedure: control of the ... reported in the journal Biomaterials on January 26, ...
... has become a standard tool in the search for ... disaster, but until now there has been very little ... policy challenges associated with this new use of genetic ... National Institutes of Health (NIH) has awarded Carnegie ...
Cached Biology Technology:Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 2Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 3Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 4Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 5Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 6Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy 7Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 2CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 3CMU Receives $1.2 Million NIH Grant To Develop Ethics, Policy Recommendations for Post-Conflict, Post-Disaster DNA ID Practices 4
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... mice responsible for repairing DNA strands damaged by oxidation ... that such stress contributes to the development of cancer. ... DNA Repair by researchers at the National Institute ... University (OHSU) and the New York University School of ...
... measure organic contaminants in human body fluids, the National ... four new Standard Reference Materials (SRMs) available for purchase. ... and Prevention (CDC), the human milk and serum SRMs ... pesticides, commonly found in the U.S. population. Scientists at ...
... Netherlands: For the first time, researchers have been able ... of IVF treatment in blood. Dr. Cathy Allen, from the ... the European Society of Human Reproduction and Embryology today (Wednesday ... works for some patients but not for others. Previous ...
Cached Biology News:Genetically engineered mice yield clues to 'knocking out' cancer 2NIST issues human milk and blood serum SRMs for contaminant measurements 2Will IVF work for a particular patient? The answer may be found in her blood 2Will IVF work for a particular patient? The answer may be found in her blood 3